80% of chronic and recurrent infections are caused by biofilms. Bacteria form biofilms as a protective shield against the immune system and antibiotics. Within biofilms, bacteria thrive with an optimum environment to multiply, meaning that the infection worsens and standard treatments fail.
BioTryp have developed a class of small molecules which inhibit biofilm formation, nipping an infection in the bud. By targeting bacteria’s key defence mechanism, BioTryp’s technology has the potential to revolutionise how we treat infection, providing a much needed alternative to traditional antibiotic treatments.
Our first indication is Urinary Tract Infections (UTIs)
UTIs are the most common bacterial infection and the leading cause of bloodstream infections. Affecting 1 in 2 women and 1 in 10 men, UTIs are responsible for 17% of all hospital-acquired bloodstream infections. At present, the only treatment option is antibiotics, where current front-line antibiotics are failing due to increasing widespread resistance. BioTryp’s disruptive technology targets bacterial biofilms forming on the bladder wall and urinary catheters, presenting a game-change in how we treat UTIs.
Company Details
- Employees
- 3
- Founded
- 2023
- Address
- Cambridge, Gb
- Industry
- Biotechnology
- Website
- http://www.biotryp.com
- Keywords
- facilities.
- HQ
- Cambridge
Biotryp Therapeutics Questions
Biotryp Therapeutics's website is http://www.biotryp.com
Biotryp Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/biotryp-therapeutics
Biotryp Therapeutics has
3 employees.
View email and phone details for 3
employees at Biotryp Therapeutics.
Biotryp Therapeutics's industry is
Biotechnology
Biotryp Therapeutics's top competitors are
Feyenally,
Labplus,
Bitbrain,
Xterna,
Nanomation,
Mendelian,
Cardiology Devices Ltd,
Healthspan Biotics,
Cambridge Nucleomics,
Bravelycultured.
Biotryp Therapeutics's categories are Biotechnology
Biotryp Therapeutics's founding year is 2023
